Options run thin for Sangamo Therapeutics after Pfizer deal crashes - San...

Published on 31 Dec 2024 on The Business Journals

Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with Sangamo Therapeutics...

Read the rest of the article

Start tracking your investments with Statfolio

Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with Sangamo Therapeutic...

The Business Journals 31 Dec 2024

Pfizer move means Sangamo won’t receive an expected payout in the first quarter, creating a cash...

Market Watch 31 Dec 2024

Investors continued to sell off shares in Sangamo Therapeutics Inc. (NASDAQ:SGMO) before market o...

Insider Monkey · via Yahoo Finance 31 Dec 2024

(Bloomberg) -- Sangamo Therapeutics Inc. shares fell the most in 16 years after Pfizer Inc. ended...

Bloomberg · via Yahoo Finance 31 Dec 2024

On Monday, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercializatio...

Benzinga · via Yahoo Finance 31 Dec 2024

Sangamo Therapeutics Inc (NASDAQ:SGMO) announced on Monday that Pfizer (NYSE:PFE) has ended their...

Investing.com 31 Dec 2024

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Sangamo...

Zacks · via Yahoo Finance 31 Dec 2024

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are goi...

Insider Monkey · via Yahoo Finance 31 Dec 2024

Upfront License Fees and Milestone Payments: Received $50 million from Genentech. Cash Runway:...

GuruFocus.com · via Yahoo Finance 13 Nov 2024

Key Insights Sangamo Therapeutics will host its Annual General Meeting on 4th of JuneSalary of US...

Simply Wall St. via Yahoo Finance 29 May 2024